{
    "symbol": "XLV",
    "slug": "xlv",
    "display_name": "XLV",
    "category": "etf",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/asset/xlv",
    "lang": "en",
    "as_of": "2026-05-22T16:03:58+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 0,
        "bearish": 1,
        "neutral": 0,
        "explicit": 0,
        "inferred": 1,
        "avg_impact": 2,
        "avg_confidence": 30,
        "last_signal_at": "2026-05-18 15:49:07",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Supreme Court ruling on Lilly sets potential precedent for Medicaid cases",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Other pharma companies may have stronger defenses",
            "count": 1
        },
        {
            "text": "Market may not view this as a sector-wide issue",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-05-18 15:49:07",
            "sentiment": "Bearish",
            "impact_score": 2,
            "confidence_score": 30,
            "mention_type": "inferred",
            "timeframe": "short-term",
            "region": "US",
            "reasoning": "The Supreme Court's decision against a major pharmaceutical firm may signal heightened legal risk for the sector, as other companies face similar Medicaid fraud allegations. This could weigh on XLV, which holds significant weight in pharma stocks.",
            "article": {
                "title": "Eli Lilly Loses Supreme Court Bid, Faces $194 Million Medicaid Payment",
                "url": "https://finscans.com/news/eli-lilly-loses-supreme-court-bid-faces-194-million"
            }
        }
    ]
}